Materiality
85.25
m&a
Source
External coverage
Decided
2026-10-09
Viatris agreed to acquire Pacira for $36.50 per share in cash ($1.65 billion); the companies expect closing by year-end 2026, subject to customary conditions. Viatris says the deal is expected to be immediately accretive and to add two marketed, patent-protected pain medicines. [Viatris press release](https://newsroom.viatris.com/2026-10-08-Viatris-Agrees-to-Acquire-Pacira-BioSciences,-Advancing-Its-Innovative-Medicines-Strategy-and-Becoming-a-Leader-in-Non-Opioid-Pain-Therapies)
View event details1 more curated